Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.
On the company’s first-quarter 2026 earnings call, Chief Executive Officer Jeffrey S. Hackman called 2026 “a defining period” for Fennec, citing progress in commercial execution, clinical interest in PEDMARK and the company’s financial position. PEDMARK is approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors to reduce the risk of cisplatin-induced ototoxicity, or permanent hearing loss.
